VEGFA and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Choueiri et al. have reported the effect of anti-vascular endothelial growth factor (VEGF) therapies (sunitinib, sorafenib, and monoclonal anti-VEGF antibodies) in 15 patients with metastatic Xp11.2 tRCC, with objective response rates of 66.7% [20].